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To the Editor:
We read with interest the recently published article by
Zao et al. [1]. In this study they compared the performance of
different guidelines for initial dosing of intravenous busulfan
in children. Their results indicated that 12 identiﬁed guide-
lines vary in their ability to achieve the conventional thera-
peutic target range (900 to 1500 mM/min) of busulfan area
under the concentration time curve (AUC). We have several
concerns regarding the methods used in their study, and
several points should be clariﬁed for correct interpretation of
their results by readers.
First, they used the AUC estimated in 111 children as the
reference value for all simulations of dosing guidelines.
Therefore, the precision of the AUC estimation in those 111
children is critical in this work. However, the authors provide
little information on this point. Apparently, they used 2
methods to estimate the individual AUC: a 1-compartment
model implemented in WinNonLin and a previously pub-
lished regression equation based on limited-sampling strat-
egy. Several points are unclear:
 Why did the author use 2 methods instead of 1?
 Which method was used for the estimation of pharma-
cokinetic parameters with the 1-compartment model?
Also, the number of samples per patient, the sample day, the
sampling times, and the typeofAUC(AUC fromtime0 to6hours
or from 0 to inﬁnity) are unknown but are all important in the
precisionofAUCestimation. Theperformanceof eachmethod in
estimating the AUC should also be provided, because a precise
and unbiased estimation is required for performing subsequent
simulations based on those AUC values.
Second, no information is provided about the busulfan assay
method. Theprecisionof the assaymethod is notprovided, even
though it has been shown that the between-run precision can
varybya factorof 2 (from7% to15% [2-7]). This can inﬂuence the
AUC estimation. Moreover, no information has been provided
about the storage of plasma samples. Busulfan plasma samples
need to be place in an ice bath at 4C for a 24-hour maximum
delay and then stored at 20C until the assay [4,8].
Third, Zao et al. simulated the AUC achieved with the initial
dosing regimen of busulfan recommended by various
guidelines. For each patient simulated busulfan AUCs were






where Doseproposed is the dose proposed by the dosing
guidelines andAUCobserved is the busulfan AUC calculatedwith
the Doseinitial (from their retrospective chart review) and
either a 1-compartmentmodel or a limited-sampling strategy.
There is a lack of important details on this calculationof the
simulated AUC. Is it the AUC per administration (AUC0-6)
reached at the steady state or the mean of 16 AUC0-6? It is
noteworthy that this calculation is valid only if AUCsimulated is
the AUC during a dose interval at the steady state and if
AUCobserved is theAUC fromtime0 to inﬁnityafter a single dose
[9]. Because there is a substantial accumulation of busulfan
after repeated i.v. administrations, the AUC0-6 observed over
the ﬁrst dosing interval is signiﬁcantly lower than that at the
steady state and should never be used in such calculation.
The objective of the study from Zao et al. was valuable and
clinically relevant. It is likely that the author’s conclusion
that AUC target attainment rates substantially vary between
the various dosing guidelines of busulfan is correct. However,
important details on the pharmacokinetic calculations per-
formed with both the real and simulated dataset are lacking,
and this make the validity of the results uncertain.
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